|
|
|
17.09.26 - 12:54
|
Russian Frigate Fires Flares At Danish Military Helicopter, Copenhagen Summons Ambassador (ZeroHedge)
|
|
|
Russian Frigate Fires Flares At Danish Military Helicopter, Copenhagen Summons Ambassador
There's been another dangerous incident and major 'close call' involving a Russian ship in international waters off Europe.
In this case, which unfolded Monday, a Danish military helicopter reportedly hovered near a Russian military frigate, seeking to monitor and photograph it.
Illustrative, via Naval Technology
Soon after, according to the account of Danish military officials, the Fennec military helicopter was fired upon by flares from the Russian ship.
It happened in the Baltic Sea, after which Moscow's ambassador in Copenhagen, Vladimir Barbin, laid blame solely on the Danish side for the helicopter's "dangerous maneuvers".
One of the flares, which are typically only used for warning signals at sea when a ship is distressed, is said to have passed dangerously close to the helicopter.
Danish Prime Minister Mette Frederiksen called the incident serious and framed it as an extension of ...
|
|
|
|
|
|
|
|
|
|
|
05.08.26 - 13:06
|
Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026 (GlobeNewswire EN)
|
|
|
RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2026 financial results before the opening of the U.S. financial markets on Tuesday, August 11, 2026. Management will host a conference call and webcast that day to discuss the Company's financial and business results....
|
|
|
|
|
|
|
22.06.26 - 12:03
|
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire EN)
|
|
|
RESEARCH TRIANGLE PARK, N.C., June 22, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 15,000 of the Company's common shares to one new non-executive employee of the Company with a grant date of June 22, 2026 under the Company's 2026 Equity Inducement Plan (the “Inducement Plan”). The ISOs were granted as inducements material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
15.06.26 - 12:03
|
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire EN)
|
|
|
RESEARCH TRIANGLE PARK, N.C., June 15, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 10,000 of the Company's common shares to one new non-executive employee of the Company with a grant date of June 15, 2026 under the Company's 2026 Equity Inducement Plan (the “Inducement Plan”). The ISOs were granted as inducements material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
10.06.26 - 22:33
|
Fennec Announces Results of Annual Meeting (GlobeNewswire EN)
|
|
|
RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 28, 2026 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held online on June 10, 2025....
|
|
|
|
|
|
|
18.05.26 - 22:33
|
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
RESEARCH TRIANGLE PARK, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on May 11, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of stock option awards (“Stock Options”) to purchase an aggregate of 50,000 of the Company's common shares to three new non-executive employees of the Company with a grant date of May 18, 2026 under the Company's 2026 Equity Inducement Plan (the “Inducement Plan”). The Stock Options consist of incentive stock options to purchase an aggregate of 49,141 shares and nonqualified stock options to purchase an aggregate of 859 shares. The Stock Options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
|
|
|
|
|
|
|
|
07.05.26 - 12:39
|
Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026 (GlobeNewswire EN)
|
|
|
RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2026 financial results before the opening of the U.S. financial markets on Thursday, May 14, 2026. Management will host a conference call and webcast that day to discuss the Company's financial and business results....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
